Patient characteristics in the study
| No. of patients . | N = 329 . |
|---|---|
| Sex | |
| Male | 223 (67.8) |
| Female | 106 (32.2) |
| Median age at VTE, y (range) | 57 (16-85) |
| Index VTE | |
| PE | 167 (50.8) |
| DVT | 154 (46.8) |
| PE + DVT | 8 (2.4) |
| Anticoagulant choice for initial treatment period | |
| Apixaban | 26 (7.9) |
| Rivaroxaban | 231 (70.2) |
| Edoxaban | 3 (0.9) |
| Dabigatran | 2 (0.6) |
| Warfarin | 66 (20.1) |
| Phenindione | 1 (0.3) |
| DASH score | |
| −2 | 3 (0.9) |
| −1 | 7 (2.1) |
| 0 | 22 (6.7) |
| 1 | 142 (43.2) |
| 2 | 57 (17.4) |
| 3 | 88 (26.7) |
| 4 | 10 (3.0) |
| Positive D-dimer | 131 (39.8) |
| No. of patients . | N = 329 . |
|---|---|
| Sex | |
| Male | 223 (67.8) |
| Female | 106 (32.2) |
| Median age at VTE, y (range) | 57 (16-85) |
| Index VTE | |
| PE | 167 (50.8) |
| DVT | 154 (46.8) |
| PE + DVT | 8 (2.4) |
| Anticoagulant choice for initial treatment period | |
| Apixaban | 26 (7.9) |
| Rivaroxaban | 231 (70.2) |
| Edoxaban | 3 (0.9) |
| Dabigatran | 2 (0.6) |
| Warfarin | 66 (20.1) |
| Phenindione | 1 (0.3) |
| DASH score | |
| −2 | 3 (0.9) |
| −1 | 7 (2.1) |
| 0 | 22 (6.7) |
| 1 | 142 (43.2) |
| 2 | 57 (17.4) |
| 3 | 88 (26.7) |
| 4 | 10 (3.0) |
| Positive D-dimer | 131 (39.8) |
All values are reported as n (%) unless otherwise indicated.
PE, pulmonary embolism.